» Articles » PMID: 2517321

Renal Prognosis in Alport's and Related Syndromes: Influence of the Mode of Inheritance

Overview
Date 1989 Jan 1
PMID 2517321
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Progressive hereditary nephritis is subdivided into Alport's syndrome (with extrarenal involvement) and hereditary nephritis without deafness. Three modes of inheritance have been described: X-linked dominant, autosomal dominant, and autosomal recessive. We reviewed the mode of inheritance in 48 kindred with hereditary nephritis (41 with Alport's syndrome and 7 with hereditary nephritis without deafness). It was presumed X-linked dominant in 34 Alport's syndrome and 6 hereditary nephritis without deafness, autosomal dominant in five hereditary nephritis and one hereditary nephritis without deafness, and autosomal recessive in two Alport's syndrome. We studied the cumulative renal survival of 149 patients, 128 (76 males, 52 females) with Alport's syndrome and 21 (10 males, and 11 females) with hereditary nephritis without deafness. Major prognostic factors were the patient's sex (median renal survival in males and females being respectively 32 versus 61 years in Alport's syndrome and 34 versus 57 years in hereditary nephritis without deafness), and the mode of inheritance (median renal survival in males being 25 years in X-linked dominant Alport's syndrome versus 51 years in autosomal dominant Alport's syndrome). The presence of hearing loss in the kindred or in the patient himself did not appear as a significant prognostic factor. We conclude that Alport's syndrome and hereditary nephritis without deafness are predominantly X-linked dominant diseases with the same renal outcome, and that in Alport's syndrome the patient's sex and the mode of inheritance are two independent prognostic factors.

Citing Articles

Alport Syndrome: Clinical Spectrum and Therapeutic Advances.

De Gregorio V, Caparali E, Shojaei A, Ricardo S, Barua M Kidney Med. 2023; 5(5):100631.

PMID: 37122389 PMC: 10131117. DOI: 10.1016/j.xkme.2023.100631.


Alport syndrome misdiagnosed with IgA nephropathy from familial history: a case report and brief review.

Rahimzadeh H, Ajlou S, Nili F, Razeghi E BMC Nephrol. 2023; 24(1):97.

PMID: 37059980 PMC: 10105455. DOI: 10.1186/s12882-023-03165-7.


Next-generation sequencing in patients with familial FSGS: first report of collagen gene mutations in Tunisian patients.

Ammar S, Kanoun H, Kammoun K, Domingo-Gallego A, Ruiz P, Lorente-Grandoso L J Hum Genet. 2021; 66(8):795-803.

PMID: 33654185 DOI: 10.1038/s10038-021-00912-2.


Population-based studies reveal an additive role of type IV collagen variants in hematuria and albuminuria.

Barua M, Paterson A Pediatr Nephrol. 2021; 37(2):253-262.

PMID: 33635378 DOI: 10.1007/s00467-021-04934-y.


Genotype-phenotype correlation and prognostic impact in Chinese patients with Alport Syndrome.

Shang S, Peng F, Wang T, Wu X, Li P, Li Q Mol Genet Genomic Med. 2019; 7(7):e00741.

PMID: 31144478 PMC: 6625365. DOI: 10.1002/mgg3.741.